The Curative Effect And The VEGF, BFGF, MMP-9Change In Serum Of Propranolol Treatment In Proliferative Hemangioma

Objective: By the observation of the efficacy and safety of oral propranolol treatmentin proliferative hemangiomas clinical, and by the detection of children before andafter medication serum VEGF, bFGF, MMP-9concentration changes, reveals thepossible mechanism of the propranolol treatment in proliferative hemangioma, and toprovide a preliminary theoretical basis of propranolol treatment in proliferativehemangioma.Methods:129cases of infants with proliferative phase of my out-patient clinics andwards hemangioma patients was collected as research subjects from September2009to December2012. According to the opinion of the children’s family, the case wasdivided into treatment group and observation group.97patients for the treatmentgroup was receipted to oral propranolol treatment,1.5mg/kg·d a morning;32cases inthe observation group to outpatient follow-up observation. Medication and observedafter2months as the base, efficacy excellent, good to be valid and poor to be invalid.Comparing the two groups of children with hemangioma changes to determine theeffect of the difference. And to detect changes in heart rate, blood glucose, liverfunction, renal function and thyroid function of treatment group before and aftermedication. The consent of the families of the children agreed to the extraction beforetaking the20cases and eight weeks after taking the blood using the ELISA method inserum VEGF, bFGF, MMP-9of concentration.Results: Treatment group, excellent in27cases, good in34cases, medium in35cases, poor in1case; the total efficiency is98.97%. Observation group, excellent in0cases, good in0cases, medium in10cases and poor in22cases, the total efficiency is31.25%.There were significant statistical differences between the two groups, heart rate change in the treatment group before and after medication, but children with nodiscomfort and other symptoms; blood glucose, liver function, renal function, nosignificant difference before and after medication. The FT3changes in thyroidfunction before and after medication was not statistically significant, and FT4concentration raises, sTSH concentration reduces, both changes were statisticallysignificant;7cases of loss of appetite, diarrhea and other gastrointestinal reactions.Medication after8weeks the concentration of VEGF (142.6950±18.83824), bFGF(38.8450±5.83790), MMP-9(279.9350±29.79854) in serum significantly reducedthan before taking VEGF (264.182515.32993), bFGF (59.4100±4.02030), MMP-9(411.2080±28.35919), there is a statistically significant difference between the twocases.Conclusion:1.Apply propranolol to oral treatment in proliferative phasehemangioma, hemangioma growth can be suppressed, and to promote its subsided,less side effects, safety, may be considered as a first-line drug therapy.2.After8weeks of medication serum VEGF, bFGF, MMP-9concentration wassignificantly lower than before the medication, with the decline in the concentrationof these three indicators, hemangioma stop the growth or regression, which suggeststhat one of the propranolol treatment in proliferative hemangioma mechanisms shouldbe related to the reduction of VEGF, bFGF, MMP-9expression.